Beximco Pharmaceuticals Limited
BXP.L · LSE
6/30/2024 | 6/30/2023 | 6/30/2022 | 6/30/2021 | |
|---|---|---|---|---|
| Revenue | £44,391,604 | £39,266,662 | £34,669,172 | £29,493,574 |
| % Growth | 13.1% | 13.3% | 17.5% | – |
| Cost of Goods Sold | £24,757,617 | £22,164,434 | £18,854,920 | £15,570,072 |
| Gross Profit | £19,633,987 | £17,102,229 | £15,814,252 | £13,923,502 |
| % Margin | 44.2% | 43.6% | 45.6% | 47.2% |
| R&D Expenses | £2,999 | £363,020 | £281,216 | £234,683 |
| G&A Expenses | £709,232 | £667,567 | £1,163,406 | £896,649 |
| SG&A Expenses | £5,595,537 | £5,246,761 | £8,912,966 | £7,272,795 |
| Sales & Mktg Exp. | £4,886,304 | £4,579,193 | £7,749,560 | £6,376,146 |
| Other Operating Expenses | £5,361,080 | £4,289,564 | -£255,716 | -£341,872 |
| Operating Expenses | £10,959,616 | £9,899,345 | £8,938,466 | £7,165,606 |
| Operating Income | £8,674,371 | £7,216,240 | £6,901,286 | £6,650,707 |
| % Margin | 19.5% | 18.4% | 19.9% | 22.5% |
| Other Income/Exp. Net | -£1,148,895 | -£1,147,471 | -£194,799 | -£273,159 |
| Pre-Tax Income | £7,525,476 | £6,068,769 | £6,686,945 | £6,377,548 |
| Tax Expense | £1,658,704 | £1,544,300 | £1,688,317 | £1,211,798 |
| Net Income | £5,829,529 | £4,614,066 | £5,123,137 | £5,127,694 |
| % Margin | 13.1% | 11.8% | 14.8% | 17.4% |
| EPS | 13.07 | 10.34 | 11.48 | 11.49 |
| % Growth | 26.4% | -9.9% | -0.1% | – |
| EPS Diluted | 13.07 | 10.34 | 11.48 | 11.49 |
| Weighted Avg Shares Out | 446,112 | 446,112 | 446,112 | 446,112 |
| Weighted Avg Shares Out Dil | 446,112 | 446,112 | 446,112 | 446,112 |
| Supplemental Information | – | – | – | – |
| Interest Income | £15,773 | £5,530 | £3,055 | £2,377 |
| Interest Expense | £1,159,702 | £1,285,698 | £1,001,836 | £858,685 |
| Depreciation & Amortization | £1,993,810 | £2,060,503 | £1,667,010 | £203,964 |
| EBITDA | £10,640,325 | £9,370,933 | £8,246,834 | £7,387,386 |
| % Margin | 24% | 23.9% | 23.8% | 25% |